LENZ — LENZ Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$5.34
+$0.11 (+2.20%)
LENZ Therapeutics Inc (LENZ) is a biotechnology company listed on NASDAQ. It is led by Evert B. Schimmelpennink, based in 201 Lomas Santa Fe Drive, Solana Beach, CA, United States, 92075, with about 152 employees. LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Net income was -$16.7M. LENZ currently screens at market cap $223.6M.
Use this LENZ page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the LENZ quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the LENZ SEC filings page. Lician reads the product cache first so this HTML stays unique to LENZ Therapeutics Inc even when a live quote feed is slow.
About LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
LENZ Key Statistics
Market Cap
$223.56M
Volume
295,042
Previous Close
$4.59
Day Range
$4.58 – $4.81
EPS
-$2.34
Revenue
$0.00
Net Income
-$49.77M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
152
LENZ Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$49.77M | -$124.65M | -$101.05M | -$70.76M |
| EPS (Diluted) | -$2.34 | -$35.71 | -$1.84 | -$2.45 |
Total Assets
$215.30M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$20.16M
Operating Cash Flow
-$59.39M
Free Cash Flow
$0.00
LENZ Therapeutics Inc Company Information
- President, CEO, Secretary & Director
- Evert B. Schimmelpennink
- Headquarters
- 201 Lomas Santa Fe Drive, Solana Beach, CA, United States, 92075
- Website
- www.lenz-tx.com
- Phone
- 858 925 7000
- IPO / Founded
- 2021-06-25
- Sector
- Healthcare
- Industry
- Biotechnology